• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Audio Journal of Prostate Cancer Special Edition 2005

0
  • by alexperjescuadmin
  • in Oncology
  • — 14 Jan, 2006

Reporting from:
2005 Multidisciplinary Prostate Cancer Symposium, February 17-19, Hyatt Grand Cypress, Orlando, Florida
Scientific Editors:

George Canellos, Dana-Farber Cancer Institute, Boston
Gordon McVie, European Institute of Oncology, Milan
Pat Price, Christie Hospital, Manchester
Gianni Bonadonna, Istituto Nazionale Tumori, Milan
Producer: Derek Thorne

In this edition:

Will they or won’t they relapse? For patients with prostate cancer, their PSA velocity before radical prostatectomy best pinpoints the risk of relapse, according to Deep Patel.

Brachytherapy, rather than external beam radiation, may be the best option for patients with intermediate-risk prostate cancer, according to Vinai Gondi.

David Dearnaley has been using the latest precision radiotherapy tool, Intensity Modulated Radiotherapy – IMRT, successfully to treat affected nodes in locally advanced prostate cancer.

A new study reveals the possibility of extending life among patients with androgen independent prostate cancer. Eric Small discusses the final survival data from a phase-three trial of the vaccine APC 8015.

Interviews in this edition:

1. Pre-op PSA Velocity: Predicts Relapse after Radical Prostectomy

Abstract 68
Deep Patel, Stanford University School of Medicine

In an investigation of 200 patients with prostate cancer the rate of change of prostate specific antigen levels before radical prostatectomy proved to be an independent prognostic factor for the risk of relapse.

2. Brachytherapy: Superior Survival in Patients with Intermediate Risk Prostate Cancer

Abstract 74
Vinai Gondi, Columbia University, New York

An investigation of brachytherapy found that it gave superior biochemical disease-free survival among 350 patients diagnosed as having intermediate-risk prostate cancer.

3. Higher Doses of Conformal Radiation Slow Prostate Cancer Progression

Abstract 58
Carl Rossi, Loma Linda University Medical Center

The use of a proton-beam boost -as part of a high-dose conformal radiotherapy schedule – has brought big advantages among patients with low or intermediate risk prostate cancer.

COMMENT: Mack Roach, UCSF Comprehensive Cancer Center, San Francisco

4. Risk of Sexual Dysfunction and Prostate Cancer Therapy

Abstract 59
Joycelyn Speight, UCSF Comprehensive Cancer Center

A study of 2 000 patients found no difference in sexual dysfunction between the treatment options available for prostate cancer patients by the time follow up goes out to four years. But brachytherapy still had the least impact on quality of life early on in treatment.

COMMENT: Mack Roach, UCSF Comprehensive Cancer Center, San Francisco

5. Intensity Modulated Radiotherapy to Treat Nodes in Locally Advanced Prostate Cancer

Abstract 179
David Dearnaley, Royal Marsden Hospital, Institute of Cancer Research, Surrey

Intensity Modulated Radiotherapy – IMRT has been used successfully to treat affected nodes in locally advanced disease.

6.Prostate Cancer Vaccine Is First to Increase Survival

Abstract 264
Eric Small, University of California, San Francisco

The possibility of extending life among patients with androgen independent prostate cancer has emerged from a new study. The final survival data presented from a phase-three randomized placebo-controlled trial of the vaccine APC 8015 show a positive benefit.

7.Natural History of Rising Serum PSA in Men with Castrate Non-Metastatic Prostate Cancer

Abstract 268
Matthew Smith, Massachusetts General Hospital, Boston

Among patients with non-metastatic disease, rising PSA despite androgen deprivation therapy is still consistent with an indolent natural history. Baseline PSA, however, along with PSA velocity, independently predicts bone metastasis and survival.

8.Zoledronic Acid Reduces the Survival-Adjusted Cumulative Incidence of Radiation to Skeletal Complications in Advanced Prostate Cancer

Abstract 282
Pierre Major, McMaster University, Ontario

Palliative use of bisphosphonates off-study has now been investigated by a multiple event analysis which allows for changing event rates and varying patient survival. Using zoledronic acid can significantly reduce the need for bone irradiation in patients with advanced disease.

9.Tumor Suppressor Gene p53 Predicts Aggressive Prostate Cancer

Abstract 62
Mack Roach, UCSF Comprehensive Cancer Center, San Francisco

Predicting aggressive disease may be easier following results from a study looking at the tumor suppressor gene p53. Mingxin Che from Wayne State University in Detroit presented data on disease progression and survival among nearly 800 patients with locally advanced prostate cancer. Mack Roach discusses the significance of Dr Che’s results.

Share

You may also like...

  • Clear-cell renal cell cancer: first molecular prognostic marker also brings scope for drug targeting Clear-cell renal cell cancer: first molecular prognostic marker also brings scope for drug targeting 27 Feb, 2014
  • Young Women with HER2+ Early Breast Cancer Better with Mastectomy Young Women with HER2+ Early Breast Cancer Better with Mastectomy 24 Aug, 2016
  • Volker Heineman Cetuximab better than bevacizumab first-line in KRAS wild type expressing colorectal tumours 21 Jun, 2013
  • Audio Journal of Oncology in Advance – March 1st, 2007 Audio Journal of Oncology in Advance – March 1st, 2007 2 Mar, 2007

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Audio Journal of Oncology 14.2, March 2006
  • Next story Audio Journal of Hematologic Malignancy Special Edition 2005
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Brachytherapy “Excellent” After Breast…
    • Microbiome Diversity Key To Survival After…
    • Ibrutinib: New Frontline Standard for Chronic…
    • Cervical Cancer: No Ureteral Stricture Increase With…
    • Image-Guided Radiotherapy: Positioning Errors Affect…
  • Home
  • Oncology
  • Audio Journal of Prostate Cancer Special Edition 2005

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.